Data Sheet (Cat.No.T13125L)

TD-0212 TFA

Chemical Properties

CAS No. : 1073549-11-7

Formula: C30H35F4N3O6S

Molecular Weight: 641.67

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.



Biological Description

Description	TD-0212 TFA is an orally active dual pharmacology compound, functioning as an antagonist of the angiotensin II type 1 receptor (AT1) with a pKi of 8.9, and as an inhibitor of neprilysin (NEP) with a pIC50 of 9.2.
Targets(IC50)	RAAS,Neprilysin,Others
In vitro	TD-0212 exhibits improved dual AT1/NEP inhibition activity and may present a reduced angioedema risk compared to dual ACE/NEP inhibition.
In vivo	In renin-dependent and non-dependent hypertension models, TD-0212 can lower blood pressure, similar to omapatrilat and the combination of AT1 receptor antagonist and NEP inhibitor.

Solubility Information

Solubility	DMSO: 125 mg/mL (194.8 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween-80+45% Saline: 3.3 mg/mL (5.14 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.5584 mL	7.7922 mL	15.5843 mL
5 mM	0.3117 mL	1.5584 mL	3.1169 mL
10 mM	0.1558 mL	0.7792 mL	1.5584 mL
50 mM	0.0312 mL	0.1558 mL	0.3117 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

McKinnell RM, et al. Discovery of TD-0212, an Orally Active Dual Pharmacology AT1 Antagonist and Neprilysin Inhibitor (ARNI). ACS Med Chem Lett. 2018 Dec 3;10(1):86-91.